Purple Biotech Hits Manufacturing Milestone for IM1240
Ticker: PPBT · Form: 6-K · Filed: Oct 29, 2025 · CIK: 1614744
Sentiment: neutral
Topics: biotech, manufacturing, drug-development
TL;DR
Purple Biotech hit a manufacturing milestone for IM1240, advancing their CAPTN-3 platform.
AI Summary
On October 29, 2025, Purple Biotech Ltd. announced a significant manufacturing milestone for IM1240, a tri-specific antibody developed on their CAPTN-3 platform. This achievement is a crucial step in the advancement of their novel therapeutic candidates.
Why It Matters
Achieving manufacturing milestones is critical for advancing drug candidates through clinical trials and towards potential commercialization, impacting the company's future revenue and the availability of new treatments.
Risk Assessment
Risk Level: medium — Manufacturing milestones are important but do not guarantee clinical success or market approval, which are subject to significant regulatory and scientific hurdles.
Key Players & Entities
- Purple Biotech Ltd. (company) — Filer of the report and developer of IM1240
- IM1240 (drug_candidate) — Tri-specific antibody developed by Purple Biotech
- CAPTN-3 Platform (platform) — Platform used to develop IM1240
- October 29, 2025 (date) — Date of the press release
FAQ
What specific manufacturing milestone did Purple Biotech achieve for IM1240?
The filing states that Purple Biotech achieved a manufacturing milestone for IM1240, a tri-specific antibody from the CAPTN-3 Platform, as detailed in their October 29, 2025 press release.
What is IM1240?
IM1240 is described as a tri-specific antibody developed by Purple Biotech Ltd. on their CAPTN-3 Platform.
What is the CAPTN-3 Platform?
The CAPTN-3 Platform is the proprietary platform developed by Purple Biotech Ltd. on which the IM1240 antibody is based.
When was this milestone announced?
The manufacturing milestone was announced on October 29, 2025.
What type of filing is this report?
This is a Form 6-K, a Report of Foreign Private Issuer, filed by Purple Biotech Ltd.
Filing Stats: 199 words · 1 min read · ~1 pages · Grade level 11.8 · Accepted 2025-10-29 07:33:58
Filing Documents
- ea0262930-6k_purple.htm (6-K) — 9KB
- ea026293001e99-1_purple.htm (EX-99.1) — 14KB
- 0001213900-25-103254.txt ( ) — 24KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. October 29, 2025 PURPLE BIOTECH LTD. By: /s/ Gil Efron Gil Efron Chief Executive Officer 2